- Home
- IMMX vs ARQQ Comparison
IMMX vs ARQQ Comparison
Compare IMMX & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- ARQQ
- Stock Information
- Founded
- IMMX 2014
- ARQQ 2017
- Country
- IMMX United States
- ARQQ United Kingdom
- Employees
- IMMX N/A
- ARQQ N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- ARQQ Computer Software: Prepackaged Software
- Sector
- IMMX Health Care
- ARQQ Technology
- Exchange
- IMMX Nasdaq
- ARQQ Nasdaq
- Market Cap
- IMMX 46.8M
- ARQQ 51.8M
- IPO Year
- IMMX 2021
- ARQQ N/A
- Fundamental
- Price
- IMMX $1.67
- ARQQ $12.40
- Analyst Decision
- IMMX Strong Buy
- ARQQ Strong Buy
- Analyst Count
- IMMX 1
- ARQQ 1
- Target Price
- IMMX $7.00
- ARQQ $50.00
- AVG Volume (30 Days)
- IMMX 89.1K
- ARQQ 212.7K
- Earning Date
- IMMX 11-12-2024
- ARQQ 12-03-2024
- Dividend Yield
- IMMX N/A
- ARQQ N/A
- EPS Growth
- IMMX N/A
- ARQQ N/A
- EPS
- IMMX N/A
- ARQQ N/A
- Revenue
- IMMX N/A
- ARQQ $740,000.00
- Revenue This Year
- IMMX N/A
- ARQQ $341.56
- Revenue Next Year
- IMMX $200.00
- ARQQ $274.91
- P/E Ratio
- IMMX N/A
- ARQQ N/A
- Revenue Growth
- IMMX N/A
- ARQQ N/A
- 52 Week Low
- IMMX $1.26
- ARQQ $3.72
- 52 Week High
- IMMX $7.75
- ARQQ $23.00
- Technical
- Relative Strength Index (RSI)
- IMMX 50.69
- ARQQ 73.61
- Support Level
- IMMX $1.65
- ARQQ $7.00
- Resistance Level
- IMMX $1.93
- ARQQ $10.68
- Average True Range (ATR)
- IMMX 0.16
- ARQQ 1.40
- MACD
- IMMX 0.01
- ARQQ 0.37
- Stochastic Oscillator
- IMMX 42.55
- ARQQ 77.21
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology which makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. Arqit delivers its symmetric key agreement technology via its QuantumCloud. Its product, QuantumCloud, enables any device to download a lightweight software agent, which can create keys in partnership with any other device. The firm operates in one segment that is, the provision of cybersecurity services via satellite and terrestrial platforms. Key revenue comes from the UK.